Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability

This article was originally published in The Pink Sheet Daily

Executive Summary

New claim puts the atypical antipsychotic on par with J&J's Risperdal.

You may also be interested in...



FDA Autism Meeting: Will It Stray From Symptoms And Treatments To Causation?

US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.

Otsuka Plans $2.8 Billion IPO To Feed Global Expansion

Otsuka Holdings Co., the parent of Japanese drug maker Otsuka Pharmaceutical Co. Ltd., has scheduled its long-planned initial public offering for December 15

Otsuka Plans $2.8 Billion IPO To Feed Global Expansion

Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel